핵의학

본문글자크기
  • [Clin Nucl Med.] Bilirubin-Related Differential Striatal [18F]FP-CIT Uptake in Parkinson Disease.

    울산의대 / 이동윤, 김재승*

  • 출처
    Clin Nucl Med.
  • 등재일
    2019 Nov
  • 저널이슈번호
    44(11):855-859. doi: 10.1097/RLU.0000000000002749.
  • 내용

    바로가기  >

    Abstract
    PURPOSE OF THE REPORT:
    Oxidative stress is a leading factor in the pathogenesis of idiopathic Parkinson disease (IPD). Two intrinsic antioxidative molecules, bilirubin and uric acid, are known to protect dopaminergic neurons from oxidative stress in IPD. The objective of this study was to determine the relationship between basal serum levels of 2 molecules and dopaminergic deficit assessed by dopamine transporter imaging with F-fluorinated-N-3-fluoropropyl-2-β-carboxymethoxy-3-β-(4-iodophenyl)nortropane ([F]FP-CIT) PET/CT in patients with early-stage drug-naive IPD.

    METHODS:
    Cases of IPD patients who possess the levels of uric acid and bilirubin within a month from [F]FP-CIT PET/CT from January 2011 to December 2016 were retrospectively reviewed. As a control, the same criteria applied to patients with essential tremor (ET). PET images were analyzed using volume-of-interest templates for 12 striatal subregions and 1 occipital area, and the specific-to-nonspecific binding ratio (SNBR) was calculated.

    RESULTS:
    One hundred five patients with drug-naive, early-stage IPD and 62 patients with ET were finally included. Levels of bilirubin were significantly higher in the IPD group than in controls (P = 0.026), and bilirubin level was the factor showing the most correlations with SNBR in IPD (P < 0.001), whereas uric acid showed no such difference or relationship. Furthermore, levels of bilirubin showed a positive correlation with SNBR in more affected posterior putamen in the IPD group (Pearson correlation coefficient, ρ = 0.456; P < 0.001), but a negative one in the ET group (ρ = -0.440, P < 0.001).

    CONCLUSIONS:
    Bilirubin, not uric acid, was the most significant antioxidant marker for dopaminergic deficit in early-stage drug-naive IPD assessed by [F]FP-CIT PET/CT.

     


    Author information

    Lee DY1, Oh M1, Kim SJ1, Oh JS1, Chung SJ2, Kim JS1.
    1
    From the Departments of Nuclear Medicine.
    2
    Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

  • 편집위원

    Bilirubin의 혈중 level이 Parkinson 질환의 진행과 관련성 있음을 보여준 임상연구로 항산화가 Parkionson 질환의 진행에 영향을 미침을 보여주었음. 신경핵의학 의사와 신경퇴행성질환 관심 임상가에게 유용한 정보를 제공할 논문으로 생각됨.

    2020-01-03 15:45:34

  • 덧글달기
    덧글달기
       IP : 3.19.31.73

    등록